(Q39300555)

10 September 2017

title

Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro (English)

1 reference

adaptive radiation therapy

10 September 2017

main subject

0 references

1 reference

M Saki

1

1 reference

10 September 2017

M Toulany

2

1 reference

10 September 2017

W Sihver

3

1 reference

10 September 2017

M Zenker

4

1 reference

10 September 2017

J-M Heldt

5

1 reference

10 September 2017

B Mosch

6

1 reference

10 September 2017

H-J Pietzsch

7

1 reference

10 September 2017

M Baumann

8

1 reference

10 September 2017

J Steinbach

9

1 reference

10 September 2017

H P Rodemann

10

1 reference

10 September 2017

publication date

10 August 2012

1 reference

Strahlentherapie und Onkologie

10 September 2017

published in

1 reference

10 September 2017

volume

188

1 reference

10 September 2017

issue

9

1 reference

10 September 2017

page(s)

823-832

1 reference

https://scigraph.springernature.com/pub.10.1007/s00066-012-0121-4

10 September 2017

exact match

0 references

cites work

Drug development for cancer chemoprevention: focus on molecular targets

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Cetuximab in combination therapy: from bench to clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Therapeutic options for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Radiation-induced EGFR-signaling and control of DNA-damage repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Receptor signaling as a regulatory mechanism of DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-012-0121-4

[RTOG study 0324: Cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer]

21 January 2018

1 reference

12 December 2020

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

1 reference

12 December 2020

The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining

1 reference

12 December 2020

Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells

1 reference

12 December 2020

Panitumumab (vectibix)

1 reference

12 December 2020

Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis

1 reference

12 December 2020

Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation

1 reference

12 December 2020

Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC)

1 reference

12 December 2020

10.1007/S00066-012-0121-4

Identifiers

DOI

1 reference

10 September 2017

1 reference